ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
about
Mutant HRAS as novel target for MEK and mTOR inhibitorsLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Rational design of non-resistant targeted cancer therapiesMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylationTargeting RAS-mutant cancers: is ERK the key?Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinomaSequencing-based diagnostics for pediatric genetic diseases: progress and potentialMutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.Endosomal acidification inhibitors for the treatment of BRAF mutant tumors.A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Cancer Genomics.
P2860
Q27853238-CD706D29-87B5-48AD-8420-6C68789D4802Q27853310-83522869-1887-4861-BB33-4CD95E2D23DBQ30277902-2AC01B6E-765B-4C53-B49D-E18522DA328DQ33594692-F4131E98-1786-41CF-B7EF-6633D3F14362Q36328021-85FADA4A-7616-4ED6-ADBD-CC2218C7B591Q36685109-743FFA28-0F06-4C57-8204-2DCC440661B2Q38267209-E5B6AA0F-D2F3-47CE-B4DA-24EEF484A892Q38371672-8093102C-0886-4FB5-8E80-078A3B79F054Q38758057-0DD8EB25-2959-49BB-BA98-E239BA52502FQ38764035-626D1A59-C9FA-46D4-9C4D-0FA221EFAD47Q38808985-34270757-B09B-44E2-B911-47819A67B6FEQ38812372-31C72B69-48C6-439A-B390-DB82B0B65311Q38844223-B5264BC1-5C73-458B-B201-295C2273AA36Q39968471-43B46117-5D77-4BDC-ABC6-EAA949BFEB99Q42369856-8D5D7EBA-7DB5-44D4-A124-7510ACB6F41CQ42730081-5F161E16-81FF-4CF1-9A85-9763C037610CQ47848122-85CFD215-9AFF-4E8B-AC21-2CA09192608AQ48128794-296B68A3-DFA3-4F25-9855-DE01EC63F6C2Q53243032-59A33AC8-9F8E-43CD-BA0E-614B6861EF5A
P2860
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
@en
type
label
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
@en
prefLabel
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
@en
P2093
P2860
P1433
P1476
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
@en
P2093
Daniel J Treacy
Eva M Goetz
Nikhil Wagle
P2860
P304
P356
10.1158/0008-5472.CAN-14-2073
P407
P577
2014-10-15T00:00:00Z